Cholesterol Reduces Partitioning of Antifungal Drug Itraconazole into Lipid Bilayers. 2020

Chetan Poojari, and Agata Zak, and Monika Dzieciuch-Rojek, and Alex Bunker, and Mariusz Kepczynski, and Tomasz Róg
Department of Physics, Faculty of Science, University of Helsinki, P.O. Box 64, FI-00014 Helsinki, Finland.

Cholesterol plays a crucial role in modulating the physicochemical properties of biomembranes, both increasing mechanical strength and decreasing permeability. Cholesterol is also a common component of vesicle-based delivery systems, including liposome-based drug delivery systems (LDSs). However, its effect on the partitioning of drug molecules to lipid membranes is very poorly recognized. Herein, we performed a combined experimental/computational study of the potential for the use of the LDS formulation for the delivery of the antifungal drug itraconazole (ITZ). We consider the addition of cholesterol to the lipid membrane. Since ITZ is only weakly soluble in water, its bioavailability is limited. Use of an LDS has thus been proposed. We studied lipid membranes composed of cholesterol, 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC), and ITZ using a combination of computational molecular dynamics (MD) simulations of lipid bilayers and Brewster angle microscopy (BAM) experiments of monolayers. Both experimental and computational results show separation of cholesterol and ITZ. Cholesterol has a strong preference to orient parallel to the bilayer normal. However, ITZ, a long and relatively rigid molecule with weakly hydrophilic groups along the backbone, predominantly locates below the interface between the hydrocarbon chain region and the polar region of the membrane, with its backbone oriented parallel to the membrane surface; the orthogonal orientation in the membrane could be the cause of the observed separation. In addition, fluorescence measurements demonstrated that the affinity of ITZ for the lipid membrane is decreased by the presence of cholesterol, which is thus probably not a suitable formulation component of an LDS designed for ITZ delivery.

UI MeSH Term Description Entries
D008051 Lipid Bilayers Layers of lipid molecules which are two molecules thick. Bilayer systems are frequently studied as models of biological membranes. Bilayers, Lipid,Bilayer, Lipid,Lipid Bilayer
D010713 Phosphatidylcholines Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety. Choline Phosphoglycerides,Choline Glycerophospholipids,Phosphatidyl Choline,Phosphatidyl Cholines,Phosphatidylcholine,Choline, Phosphatidyl,Cholines, Phosphatidyl,Glycerophospholipids, Choline,Phosphoglycerides, Choline
D010767 Phosphorylcholine Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction. Choline Chloride Dihydrogen Phosphate,Choline Phosphate Chloride,Phosphorylcholine Chloride,Choline Phosphate,Phosphocholine,Chloride, Choline Phosphate,Chloride, Phosphorylcholine,Phosphate Chloride, Choline,Phosphate, Choline
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D005990 Glycerol A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism. It is used as a solvent, emollient, pharmaceutical agent, or sweetening agent. 1,2,3-Propanetriol,Glycerin,1,2,3-Trihydroxypropane,Glycerine
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D017964 Itraconazole A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis. Orungal,R-51211,Sporanox,R 51211,R51211

Related Publications

Chetan Poojari, and Agata Zak, and Monika Dzieciuch-Rojek, and Alex Bunker, and Mariusz Kepczynski, and Tomasz Róg
February 1996, Journal of pharmaceutical sciences,
Chetan Poojari, and Agata Zak, and Monika Dzieciuch-Rojek, and Alex Bunker, and Mariusz Kepczynski, and Tomasz Róg
January 2003, Biophysical journal,
Chetan Poojari, and Agata Zak, and Monika Dzieciuch-Rojek, and Alex Bunker, and Mariusz Kepczynski, and Tomasz Róg
June 1995, Journal of chromatography. A,
Chetan Poojari, and Agata Zak, and Monika Dzieciuch-Rojek, and Alex Bunker, and Mariusz Kepczynski, and Tomasz Róg
May 2021, The journal of physical chemistry. B,
Chetan Poojari, and Agata Zak, and Monika Dzieciuch-Rojek, and Alex Bunker, and Mariusz Kepczynski, and Tomasz Róg
September 2009, Journal of chemical theory and computation,
Chetan Poojari, and Agata Zak, and Monika Dzieciuch-Rojek, and Alex Bunker, and Mariusz Kepczynski, and Tomasz Róg
September 2000, Biophysical journal,
Chetan Poojari, and Agata Zak, and Monika Dzieciuch-Rojek, and Alex Bunker, and Mariusz Kepczynski, and Tomasz Róg
May 1994, Biochimica et biophysica acta,
Chetan Poojari, and Agata Zak, and Monika Dzieciuch-Rojek, and Alex Bunker, and Mariusz Kepczynski, and Tomasz Róg
November 2001, The Journal of pharmacy and pharmacology,
Chetan Poojari, and Agata Zak, and Monika Dzieciuch-Rojek, and Alex Bunker, and Mariusz Kepczynski, and Tomasz Róg
March 1999, Journal of controlled release : official journal of the Controlled Release Society,
Chetan Poojari, and Agata Zak, and Monika Dzieciuch-Rojek, and Alex Bunker, and Mariusz Kepczynski, and Tomasz Róg
April 2004, Colloids and surfaces. B, Biointerfaces,
Copied contents to your clipboard!